Clinical Trial: A single-arm, phase II clinical study of orelabrutinib combined with low-dose radiotherapy in the treatment of newly diagnosed early-stage marginal zone lymphoma (MZL) (China)

China, Sept. 29 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A single-arm, phase II clinical study of orelabrutinib combined with low-dose radiotherapy in the treatment of newly diagnosed early-stage marginal zone lymphoma (MZL)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133509

Registration Time: 2026/09/28

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital of Xiamen University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=345581

Published by HT Digital Content Services with permission from Health Daily Digest....